A humanized monoclonal antibody that targets CD19+ B cells becomes the first and only FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
"As we move toward a more holistic approach to health care, integrating lifestyle modifications into clinical practice could lead to improved gastrointestinal health outcomes."